多替阿巴拉米片价格多少？

As of the end of October 2017, there were 746,000 reported surviving HIV/AIDS patients and 229,000 reported deaths across the country. The number of people receiving antiviral treatment at the end of 2016 was 495,000. Following the launch of Tivicai, a new HIV treatment drug last year, another new HIV drug from GSK has been approved for marketing in mainland China. GlaxoSmithKline (GSK) announced on January 20 that its joint venture ViiV Healthcare1's single-pill compound preparation Suimeikai (chemical name: Dolutegravir) as the core for the treatment of HIV, which is a new generation integrase inhibitor, Trivicavir (chemical name: Dolutegravir), was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. As an innovative single-tablet compound preparation with obvious clinical therapeutic advantages, Dolutegra Abalamid Tablets can provide great convenience for the treatment of HIV-infected patients. GSK has been bringing innovative, high-quality treatment solutions to HIV-infected people in China since 1999. Shuangtaizhi is GSK's first approved HIV antiviral treatment drug in China. 

Dolutegravir tablets are the only three-in-one compound drug with dolutegravir (DTG) as the core. It has the characteristics of high efficacy, good tolerability, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of HIV-infected patients, thereby improving patients' medication compliance and significantly improving their quality of life. At present, dolutea palamid tablets have been approved for marketing in 50 countries and regions, and are recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line treatment of choice for patients with newly diagnosed HIV infection. 

Regarding pricing, Dolutegra abalami tablets are currently priced at $2,880/month in the Chinese market. In an interview with a reporter from E Drug Manager, Xu Ding, vice president of government affairs and communications at GSK, said: The price of Dolutea Paramid Tablets in China is the lowest in neighboring countries and regions. Next, GSK will actively coordinate and communicate with relevant departments to promote Dolutegra Abalamid Tablets to enter China's free AIDS drug list as soon as possible, benefiting more patient groups. It is worth mentioning that Inbec, a box of 30 tablets produced by the Indian company Emcure, sells for approximately RMB 1,000, making it the most cost-effective version currently on the market.